Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 3/20 | 0.42 |
| ▸ | MME | P08473 | 5/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068583 | 1.00 | BACE1 (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL30184223 | 0.97 | BACE1 (0.43) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL31169711 | 0.91 | BACE1 (0.51) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29440233 | 0.89 | MME (0.48) | BACE1CTSDMMEACECPA1 | |
| SCHEMBL9852025 | 0.89 | MME (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29697058 | 0.89 | MME (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL9852027 | 0.89 | MME (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29517369 | 0.89 | MME (0.44) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29867829 | 0.88 | MME (0.47) | BACE1CTSDPDCD1LG2CD274ECE1 | |
| SCHEMBL29889514 | 0.88 | PDCD1LG2 (0.55) | BACE1CTSDPDCD1LG2CD274ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | BACE1 307/4885CTSD 251/4885PDCD1LG2 1212/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | BACE1 307/4885CTSD 251/4885PDCD1LG2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.